FLT3 and acute myeloid leukemia: Building on these findings, further investigations of novel treatment strategies of PKC412 in FLT3-ITD positive AML patients is of interest, and blocking of FLT3 ligand-receptor interaction as well as crucial signaling pathways could be important tools to increase the treatment response and reduce the risk of chemotherapy resistance.